- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
Ira Winer, MD, PhD, FACOG | Authors
Ira Winer, MD, PhD, Discusses Next Steps for Nemvaleukin Alfa Plus Pembrolizumab in Ovarian Cancer
May 03, 2022
Ira Winer, MD, PhD, FACOG, spoke about future directions of nemvaleukin alfa plus pembrolizumab for patients with pretreated platinum resistant ovarian cancer.
Ira Winer, MD, PhD, on Surprising Findings From ARTISTRY-1 in Ovarian Cancer
April 15, 2022
Ira Winer, MD, PhD, FACOG, spoke about high response rates observed in patients with pretreated platinum-resistant ovarian cancer from the phase 1/2 ARTISTRY-1 trial.
Ira Winer, MD, PhD, Reviews Results of the ARTISTRY-1 Trial in Ovarian Cancer
April 05, 2022
Ira Winer, MD, PhD, FACOG, spoke about patients with pretreated platinum-resistant ovarian cancer treated with nemvaleukin alfa plus pembrolizumab in the phase 1/2 ARTISTRY-1 trial.
Ira Winer, MD, PhD, Talks Best Data to Come Out of SGO 2022
March 29, 2022
Ira Winer, MD, PhD, FACOG, spoke about which presentations during The Society of Gynecologic Oncology 2022 Annual Meeting he most enjoyed.